83183-56-6

Usage

Uses

Used in Pharmaceutical Industry:
2-chloro-7-(trifluoromethyl) quinoline is used as a pharmaceutical candidate for its antimicrobial, antiviral, and anti-inflammatory properties, making it a potential treatment for various infections and inflammatory conditions.
Used in Organic Synthesis:
2-chloro-7-(trifluoromethyl) quinoline serves as a building block in organic synthesis, enabling the creation of a wide range of biologically active molecules with diverse applications in medicine and other fields.
Used in Drug Development:
As a compound with demonstrated biological activities, 2-chloro-7-(trifluoromethyl) quinoline is utilized in drug development to explore its potential as a therapeutic agent for various diseases and conditions.
Used in Chemical Industry:
2-chloro-7-(trifluoromethyl) quinoline's versatility and unique chemical structure make it a valuable component in the chemical industry for the synthesis of specialty chemicals and intermediates for further applications.

Upstream product

• 1011533-24-6 7-(trifluoromethyl)quinolin-2-ol 
• 231296-89-2 (E)-methyl 3-(2-amino-4-(trifluoromethyl)phenyl)acrylate 
• 454-79-5 2-Bromo-5-trifluoromethylaniline 
• 1011533-24-6 7-(trifluoromethyl)quinolin-2(1H)-one 

Downstream Products

• 1421348-41-5 C₂₅H₂₆F₃N₃O₃ 
• 113508-12-6 2-amino-7-(trifluoromethyl)quinoline 

Relevant academic research and scientific papers

METHODS OF CULTURING AND/OR EXPANDING STEM CELLS AND/OR LINEAGE COMMITTED PROGENITOR CELLS USING AMIDO COMPOUNDS

Provided are methods for expanding stem cells and/or lineage committed progenitor cells, such as hematopoietic stems cells and/or lineage committed progenitor cells, at least in part, by using compounds that antagonize AhR. The compounds are represented by formulae (I) (II) (III) (IV), wherein the letters and symbols a, b, c, d, e, f, g, Z, R1b, R2a and R2b have the meanings provided in the specification. Also provided are compositions comprising stem cells and/or lineage committed progenitor cells expanded by methods disclosed herein and methods for the treatment of diseases treatable by same.

AMIDO COMPOUNDS AS AhR MODULATORS

Provided herein are compounds, compositions and methods of using the compounds and compositions for the treatment of diseases modulated, as least in part, by AhR. The compounds are represented by formulae Formula (I), (II), (III), (iv): wherein the letters and symbols a, b, c, d, e, f, g, Z, R1b, R2a and R2b have the meanings provided in the specification.

QUINOLINYL GLUCAGON RECEPTOR MODULATORS

The present invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, A1, A2, A3, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.

Development of CXCR3 antagonists. Part 4: Discovery of 2-amino-(4-tropinyl)quinolines

The synthesis and biological evaluation of a novel series of 2-aminoquinoline substituted piperidines and tropanes incorporating a homotropene moiety is herein described. The series exhibits potent antagonism of the CXCR3 receptor and superior physicochem